MedTrace Logo

Liquid Biopsy in Paraneoplastic Neurological Syndromes

NCT07491328 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-03-24

No results posted yet for this study

Summary

The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients.

Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.

Conditions

  • Paraneoplastic Neurological Syndromes

Interventions

DIAGNOSTIC_TEST

CTC & ctDNA analysis

Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood

Sponsors & Collaborators

  • University of Regensburg

    collaborator OTHER

  • Universität Münster

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Medical University of Graz

    collaborator OTHER

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-20
Primary Completion
2030-12-30
Completion
2030-12-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07491328 on ClinicalTrials.gov